Pro Kidney Stock Lone Winner on Bleak Day for Wall Street

We're taking a closer look at ProKidney today, as tone of the only stocks in the green during today's session: its shares moved 4.8% compared to -2.2% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • ProKidney Corp., a clinical-stage biotechnology company, engages in developing cellular therapy cures for cancer.

  • ProKidney has moved -9.3% over the last year compared to -15.7% for the S&P 500 -- a difference of 6.3%

  • The company has a Price to Book (P/B) ratio of 300 in contrast to the S&P 500's average ratio of 2.95

  • ProKidney is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07

At Market Interference, our goal is to help educate investors about headline-making stocks. We believe informed investment decisions are good investment decisions. subscribe to our free newsletter to stay on top of each day's market movements!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.